Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBU NASDAQ:FTLF NASDAQ:JSPR NASDAQ:MDWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.78-1.4%$1.92$0.66▼$3.00$164.64M2.541.27 million shs486,025 shsFTLFFitLife Brands$18.64+0.4%$15.70$9.83▼$19.19$174.97M0.6519,641 shs5,376 shsJSPRJasper Therapeutics$2.35-3.3%$2.94$2.27▼$26.05$38.19M2.77468,864 shs107,715 shsMDWDMediWound$16.95-0.8%$18.49$14.14▼$22.50$182.31M0.2581,346 shs64,091 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences-1.64%-2.17%-9.09%+40.63%-11.33%FTLFFitLife Brands+1.92%-2.62%+11.74%+36.17%+13.80%JSPRJasper Therapeutics+2.10%-6.18%-21.86%-53.80%-89.41%MDWDMediWound-0.29%+4.91%-5.58%-12.04%-5.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.78-1.4%$1.92$0.66▼$3.00$164.64M2.541.27 million shs486,025 shsFTLFFitLife Brands$18.64+0.4%$15.70$9.83▼$19.19$174.97M0.6519,641 shs5,376 shsJSPRJasper Therapeutics$2.35-3.3%$2.94$2.27▼$26.05$38.19M2.77468,864 shs107,715 shsMDWDMediWound$16.95-0.8%$18.49$14.14▼$22.50$182.31M0.2581,346 shs64,091 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences-1.64%-2.17%-9.09%+40.63%-11.33%FTLFFitLife Brands+1.92%-2.62%+11.74%+36.17%+13.80%JSPRJasper Therapeutics+2.10%-6.18%-21.86%-53.80%-89.41%MDWDMediWound-0.29%+4.91%-5.58%-12.04%-5.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 3.00Buy$6.67273.48% UpsideFTLFFitLife Brands 2.67Moderate Buy$23.0025.58% UpsideJSPRJasper Therapeutics 2.60Moderate Buy$28.751,097.92% UpsideMDWDMediWound 2.80Moderate Buy$32.2591.57% UpsideCurrent Analyst Ratings BreakdownLatest JSPR, MDWD, FTLF, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025FTLFFitLife BrandsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/19/2025MDWDMediWoundZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025FTLFFitLife BrandsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.008/15/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$29.00 ➝ $25.007/8/2025JSPRJasper TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$5.007/8/2025JSPRJasper TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$70.00 ➝ $12.007/8/2025JSPRJasper TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$50.00 ➝ $20.007/8/2025JSPRJasper TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform7/7/2025JSPRJasper TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $20.007/7/2025JSPRJasper TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$64.00 ➝ $20.007/7/2025JSPRJasper TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$9.99M16.64N/AN/A$2.79 per share0.64FTLFFitLife Brands$64.47M2.67$1.02 per share17.97$3.93 per share4.66JSPRJasper TherapeuticsN/AN/AN/AN/A$4.11 per shareN/AMDWDMediWound$20.22M9.00N/AN/A$2.89 per share5.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)FTLFFitLife Brands$8.98M$0.8421.8016.65N/A12.63%21.70%13.45%N/AJSPRJasper Therapeutics-$71.27M-$6.01N/AN/AN/AN/A-172.28%-128.34%11/6/2025 (Estimated)MDWDMediWound-$30.22M-$2.64N/AN/AN/A-142.18%-96.71%-39.73%11/25/2025 (Estimated)Latest JSPR, MDWD, FTLF, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FTLFFitLife Brands$0.18$0.18N/A$0.18$16.17 million$16.13 million8/14/2025Q2 2025MDWDMediWound-$0.55-$1.23-$0.68-$1.23$5.68 million$5.71 million8/13/2025Q2 2025JSPRJasper Therapeutics-$1.20-$1.74-$0.54-$1.74N/AN/A8/12/2025Q2 2025CRBUCaribou Biosciences-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A6.666.66FTLFFitLife Brands0.151.710.81JSPRJasper TherapeuticsN/A2.102.10MDWDMediWoundN/A1.481.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%FTLFFitLife Brands2.32%JSPRJasper Therapeutics79.85%MDWDMediWound46.83%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences9.50%FTLFFitLife Brands61.40%JSPRJasper Therapeutics4.60%MDWDMediWound9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10093.12 million84.28 millionOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableJSPRJasper Therapeutics2016.25 million15.51 millionOptionableMDWDMediWound8010.81 million9.81 millionOptionableJSPR, MDWD, FTLF, and CRBU HeadlinesRecent News About These CompaniesSilverberg Bernstein Capital Management LLC Buys 43,591 Shares of MediWound Ltd. $MDWDSeptember 17 at 6:13 AM | marketbeat.comMediWound Ltd. (NASDAQ:MDWD) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 16 at 4:14 AM | marketbeat.comMediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressSeptember 2, 2025 | markets.businessinsider.comMediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressSeptember 2, 2025 | globenewswire.comMediWound Is A Buy Opportunity On The DipSeptember 2, 2025 | seekingalpha.comMediWound (NASDAQ:MDWD) Downgraded to "Hold" Rating by Zacks ResearchAugust 23, 2025 | marketbeat.comMediWound to Present at the H.C. Wainwright 27th Annual Global ...August 22, 2025 | morningstar.comMMediWound to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 20, 2025 | globenewswire.comMediWound Executives Purchase Shares, Signaling ConfidenceAugust 19, 2025 | msn.comMediWound (NASDAQ:MDWD) Posts Quarterly Earnings Results, Misses Expectations By $0.68 EPSAugust 18, 2025 | marketbeat.comCraig-Hallum Sticks to Their Buy Rating for Mediwound (MDWD)August 17, 2025 | theglobeandmail.comAnalysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) Second-Quarter ReportAugust 17, 2025 | finance.yahoo.comMediWound reports Q2 EPS ($1.23), consensus (57c)August 14, 2025 | msn.comMediWound Revenue Jumps 43% in Q2August 14, 2025 | aol.comAMediWound Reports Q2 2025 Financial Results and Strategic UpdatesAugust 14, 2025 | msn.comMediWound Ltd. (MDWD) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comMediWound (MDWD) Reports Q2 Loss, Beats Revenue EstimatesAugust 14, 2025 | zacks.comMediWound Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comMediWound Q2 2025 Earnings PreviewAugust 13, 2025 | msn.comMediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg UlcersAugust 13, 2025 | globenewswire.comMediWound Ltd. to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 14August 4, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJSPR, MDWD, FTLF, and CRBU Company DescriptionsCaribou Biosciences NASDAQ:CRBU$1.78 -0.03 (-1.39%) As of 03:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.FitLife Brands NASDAQ:FTLF$18.64 +0.08 (+0.40%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Jasper Therapeutics NASDAQ:JSPR$2.35 -0.08 (-3.29%) As of 03:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.MediWound NASDAQ:MDWD$16.94 -0.15 (-0.85%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
